The FDA approved record numbers of new molecular entities, orphan drugs, small-molecule generics and biosimilars in 2018. Could industry’s regulatory success of the past two years become the new normal?
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Morrison, C. Fresh from the biotech pipeline—2018. Nat Biotechnol 37, 118–123 (2019). https://doi.org/10.1038/s41587-019-0021-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-019-0021-6
- Springer Nature America, Inc.
This article is cited by
-
Opportunities in an Evolving Pharmaceutical Development Landscape: Product Differentiation of Biopharmaceutical Drug Products
Pharmaceutical Research (2021)
-
Zebrafish patient avatars in cancer biology and precision cancer therapy
Nature Reviews Cancer (2020)
-
Investigating Rates of Food and Drug Administration Approvals and Guidances in Drug Development: A Structural Breakpoint/Cointegration Timeseries Analysis
Therapeutic Innovation & Regulatory Science (2020)
-
Analytical and preparative separation of phosphorothioated oligonucleotides: columns and ion-pair reagents
Analytical and Bioanalytical Chemistry (2020)
-
The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study
Orphanet Journal of Rare Diseases (2019)